NCT02930681

Efficacy of Glucosanol™ in Reducing Post-prandial Glucose Levels in Overweight Subjects

Double-blind, Randomised, Placebo-controlled, 3-way Cross-over Study to Evaluate the Benefit of Two Glucosanol™ Dosages to Reduce Post-prandial Glucose Levels in Overweight Subjects

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: InQpharm Group · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Glucosanol had previously been proven to be effective in aiding weight loss and weight loss maintenance. Studies have also shown that Glucosanol (also known as Phaseolamin), was effective in aiding weight loss and also has evidence on reducing post-prandial glucose levels. This study is to enrich the existing evidence on dose-dependent post-prandial glucose effects of Glucosanol

Conditions

• Hyperglycemia, Postprandial

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Glucosanol 500mg
DIETARY_SUPPLEMENT	Placebo

Timeline

• Start date: 2016-08-01
• Primary completion: 2016-11-01
• Completion: 2016-11-01
• First posted: 2016-10-12
• Last updated: 2017-02-08

Locations

1 site across 1 country: Germany